Data from a Phase III study presented at the 23rd Annual European Association of Urology Congress demonstrated that the investigational GnRH blocker, degarelix…

Ferring Pharmaceuticals announced today that it has submitted applications in Europe and the United States for…

Ferring Pharmaceuticals today launches the first Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) for fundamental fertility and gynaecology research…

Ferring Pharmaceuticals announced today that it has successfully completed the pivotal phase III study for degarelix, its novel prostate cancer treatment…

For the first time a once daily dosing regime of mesalazine (Pentasa® granules) has proven to be statistically superior to…

Ferring Pharmaceuticals today announced that it had come to an agreement with Cosmo Pharmaceuticals SpA for…

Ferring Pharmaceuticals today announced changes to the company’s Board of Directors. Effective immediately, Alexandra, Countess of Frederiksborg will become a new non-executive member of the Board…

New data presented today at the European Society of Human Reproduction and Embryology (ESHRE) 2007 congress shows that…

Medical, political and demographical experts drawn from across the globe have come together this week to discuss the ongoing challenges associated with access to infertility…

Ferring Headquarters and new production facility open in Saint-Prex, Switzerland. The facility provides additional production capacity for Ferring’s dry products…